Keyword: Intercept Pharmaceuticals
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
The cash injection will also position Genfit to look to life beyond the phase 3 by supporting commercial preparations and the in-licensing of assets.
French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in patients with liver scarring by four to six months.
A phase 2 trial of Bristol-Myers' NASH candidate BMS-986036 met its primary endpoint.
Frazier Healthcare Partners has once again installed a trio of biotech veterans at the helm and put up cash to get through a vital trial.
Inventiva has raised €48 million through an IPO to take its lead candidate through phase 2b trials in NASH and systemic sclerosis.
Intercept was down 12% premarket this morning as it announced an out-of-the-blue update on its late-stage fatty liver disease test, but jumped first thing after changing its endpoints and the definition of NASH improvement for its study.
Five months after gaining FDA approval, Intercept Pharmaceuticals has now been given the CHMP nod for its new liver drug Ocaliva (obeticholic acid) for primary biliary cirrhosis (PBC).